Interleukin‐4 (IL‐4), primarily secreted by ovarian cancer cells, promotes resistance to anti‐PD‐1 immunotherapy by shaping an immunosuppressive tumor microenvironment (TME) through macrophage modulation. This evidence concerns the gene IL4 and ovarian carcinoma.